ME01318B - Makrociklički inhibitori virusa hepatitisa C - Google Patents
Makrociklički inhibitori virusa hepatitisa CInfo
- Publication number
- ME01318B ME01318B MEP-2011-194A MEP19411A ME01318B ME 01318 B ME01318 B ME 01318B ME P19411 A MEP19411 A ME P19411A ME 01318 B ME01318 B ME 01318B
- Authority
- ME
- Montenegro
- Prior art keywords
- formula
- het
- 6alkyl
- substituted
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 2
- 241000711549 Hepacivirus C Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000002757 morpholinyl group Chemical group 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- -1 polyhalo- C1-6alkyl Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 238000006751 Mitsunobu reaction Methods 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000005865 alkene metathesis reaction Methods 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000006254 arylation reaction Methods 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (16)
1. Jedinjenje, naznačeno time, da je predstavljeno sledećom formulom i njegovi N-oksidi, soli i stereoizomeri, gde svaka isprekidana linija (predstavljena sa - - - - -) predstavlja neku opcionalnu dvostruku vezu; X je N, CH, a kada X sadrži dvostruku vezu, tada je C; Rla i Rlb su, nezavisno, vodonik, C3-7cikloalkil, aril, Het, C1-6alkoksi, C1-6alkil ponekad supstituisan sa halo, C1-6alkoksi, cijano, polihaloC1-6alkoksi, C3-7cikloalkil, aril ili sa Het; ili R1a i R1b zajedno sa azotom na kojeg su spojeni formiraju od 4 do 6-člani zasićeni, delomično ne-zasićeni ili potpuno ne-zasićeni heterociklički prsten koji ponekad sadrži dodatna 1 do 3 heteroatoma od koji je svaki nezavisno izabran iz azota, kiseonika i sumpora i gde pomenuti heterociklički prsten može da ponekad bude supstituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno izabran iz grupe koja obuhvata halo, C1-6alkil, polihaloC1-6alkil, hidroksi, C1-6alkoksi, polihaloC1-6alkoksi, C1-6alkoksiC1-6alkil, karboksil, C1-6alkilkarbonil, cijano, mono- i diC1-6alkilamino, aril i arilC1-6alkil; L je direktna veza, -O-, -O-C1-4alkandiil-, -O-CO-, -O-C(=O)-NR5a- ili -O-C(=O)-NR5a- C1-4alkandiil-; R2 je vodonik, a kada X je C ili CH, R2 može takođe da bude i C1-6alkil; R3 je vodonik, C1-6alkil, C1-6alkoksiC1-6alkil, C3-7cikloalkil, amino, mono- ili diC1-6alkilamino; R4 je aril ili zasićeni, delomično ne-zasićeni ili kompletno ne-zasićeni 5 ili 6-člani monociklički ili 9 do 12-člani biciklički heterociklički prstenski sistem gde pomenuti prstenski sistem sadrži jedan azot, a ponekad i jedan do tri dodatna heteroatoma koja su izabrana iz grupe koja sadrži kiseonik, sumpor i azot i gde preostali članovi prstena su atomi ugljenika; gde pomenuti prstenski sistem može ponekad da bude supstituisan sa bilo kojim ugljenikovim ili azotnim prstenskim atomom sa jedan, dva, tri ili četiri supstituenata od kojih je svaki nezavisno izabran iz C3-1cikloalkila, arila, Het, - C(=O)NR5aR5b, -C(=O)R7, -C(=O)0R6a i C1-6alkila koji je ponekad supstituisan sa C3-7cikloalkilom, arilom, Het, -C(=O)NR5aR5b, -NR5aR5b, -C(=O)R7, -NR5aC(=O)R7, - NR5aSOpR8, -SOpR8, -SOpNR5aR5b, -C(=O)OR6 ili -NR5aC(=OR6a; i gde pomenuti supstituenti ili bilo koji ugljenikov atom iz heterocikličkog prstena mogu takođe da budu izabrani iz C1-6alkoksi, hidroksi, halo, polihalo- C1-6alkila, C1-6alkiltio, okso, cijano, nitro, azido, -NR5aR5b, -NR5aC(=O)R7, -NR5aSOpR8, -SOpR8, -SOpNR5aR5b, - C(=O)OH i -NR53C(=O)OR6a; n je 3, 4, 5 ili 6; p je 1 ili 2; svaki od R5a i R5b je, nezavisno, vodonik, C3-7cikloalkil, aril, Het, C1-6alkil koji je ponekad supstituisan sa halo, C1-6alkoksi, cijano, polihaloC1-6alkoksi, C3-7cikloalkilom, arilom ili sa Het; R6 je vodonik, C2-6alkenil, C3-7cikloalkil, Het ili C1-6alkil koji je ponekad supstituisan sa C3-7cikloalkilom, arilom ili Het; R6a je C2-6alkenil, C3-7cikloalkil, Het ili C1-6alkil koji je ponekad supstituisan sa C3-7cikloalkilom, arilom ili Het; R7 je vodonik, C1-6alkil, C3-1cikloalkil ili aril; R8 je vodonik, polihaloC1-6alkil, C3-7cikloalkil, aril, Het ili C1-6alkil koji je ponekad supstituisan sa C3-7cikloalkilom, arilom ili Het; aril kao grupa ili deo grupe je fenil, naftil, indanil ili 1, 2, 3, 4-tetra-hidronaftil, a svaki od njih može da ponekad bude supstituisan sa jednim, dva ili tri supstituenata koja su izabrana iz halo, C1-6alkila, polihaloC1-6alkila, hidroksi, C1-6alkoksi, polihaloC1-6alkoksi, C1-6alkoksiC1-6alkila, karboksila, C1-6alkilkarbonila, C1-6alkoksi-karbonila, cijano, nitro, amino, mono- ili diC1-6alkilamino, aminokarbonila, mono- ili diC1-6alkilaminokarbonila, azido, merkapto, C3-7cikloalkila, fenila, piridila, tiazolila, pirazolila, pirolidinila, piperidinila, piperazinila, 4-C1-6alkilpiperazinila, 4-C1-6alkilkarbonil-piperazinila i morfolinila; gde pomenute morfolinilne i piperidinilne grupe mogu da ponekad budu supstituisane sa jednim ili dva C1-6alkil radikala; a pomenute fenilne, piridilne, tiazolilne, pirazolilne grupe mogu ponekad da budu supstituisane sa 1, 2 ili 3 supstituenta od kojih je svaki nezavisno izabran iz C1-6alkila, C1-6alkoksi, halo, amino, mono- ili diC1-6alkilamino; Het, kao grupa ili deo grupe, je 5 ili 6-člani zasićeni, delomično ne-zasićeni ili kompletno ne-zasićeni heterociklički prsten koji sadrži 1 do 4 heteroatoma od kojih je svaki nezavisno izabran iz azota, kiseonika i sumpora i koji je ponekad kondenzovan sa nekim benzenskim prstenom, a gde pomenuta grupa Het kao celo može ponekad da bude supstituisana sa jednim, dva ili tri supstituenta od kojih je svaki nezavisno izabran iz grupe koja obuhvata halo, C1-6alkil, polihaloC1-6alkil, hidroksi, C1-6alkoksi, polihaloC1-6alkoksi, C1-6alkoksiC1-6alkil, karboksil, C1-6alkilkarbonil, C1-6 alkoksikarbonil, cijano, nitro, amino, mono- ili diC1-6alkilamino, amino- karbonil, mono- ili diC1-6alkilaminokarboni 1, C3-7cikloalkil, fenil, piridil, tiazolil, pirazolil, pirolidinil, piperidinil, piperazinil, 4-C1-6alkilpiperazinil, 4-C1-6alkilkarbonil-piperazinil i morfolinil; gde pomenute morfolinilne i piperidinilne grupe mogu ponekad da budu supstituisane sa jednim ili dva C1-6alkil radikala; a pomenute fenilne, piridilne, tiazolilne, pirazolilne grupe mogu ponekad da budu supstituisane sa 1, 2 ili 3 supstituenata od kojih je svaki nezavisno izabran iz C1-6alkila, C1-6alkoksi, halo, amino, mono- ili diC1-6alkilamino.
2.Jedinjenje u skladu sa zahtevom 1, naznačeno time, da pomenuto jedinjenje ima formulu (I -c), (I-d) ili (I-e):
3. Jedinjenje u skladu sa bilo kojem od zahteva od 1-2, naznačeno time, da (a)svaki od Rla i Rlb je, nezavisno, vodonik ili metil, etil ili tert-butil; ili (b)jedan od Rla i Rlb je ciklopropil ili fenil; ili (c)Rla i Rlb zajedno sa atomom azota na kojeg su spojeni formiraju pirolidinil, piperidinil, piperazinil, 4-C1-6alkilpiperazini1, 4-C1-6alkil-karbonilpiperazinil ili morfolinil; ili (d)jedan od R1a i R1b je neka Het grupa koja je izabrana od
4. Jedinjenje u skladu sa zahtevom 1, naznačeno time, da L je -O-, -O-CO- ili direktna veza.
5. Jedinjenje u skladu sa bilo kojim od zahteva od 1-4, naznačeno time, da Lje -O-, R4 je kinolinil (a posebno kinolin-4-il), izokinolinil (a posebno izokinolin-l-il), kinazolinil (a posebno kinazolin-4-il) ili pirimidinil (a posebno pirimidin-4-il), od koji je svaki, nezavisno, ponekad mono, di ili tri supstituisani sa C1-6alkilom, C1-6alkoksi, nitro, hidroksi, halo, trifluorometilom, -NR5aR5b, -C(=O)NR5aR5b, C3-7cikloalkilom, arilom, Het, -C(=O)OH ili -C(=O)OR6a; a gde aril ili Het su svaki nezavisno, ponekad supstituisani sa halo, C1-6alkilom, C1-6alkoksi, amino, mono- ili diC1-6alkilamino, pirolidinilom, piperidinilom, piperazinilom, 4C1-6alkilpiperazinilom (na primer, 4- metilpiperazinil) ili morfolinilom; a gde pomenute morfolinilne i piperidinilne grupe mogu ponekad da budu supstituisane sa jednim ili dva C1-6alkil radikala.
6. Jedinjenje u skladu sa bilo kojim od zahteva od 1-4, naznačeno time, da L je -O-, a R4 je (d-1) radikal sa formulom (d-2) radikal sa formulom (d-3) radikal sa formulom (d-4) radikal sa formulom ili posebno, (d-4-a) radikal sa formulom (d-5) radikal sa formulom gde u radikalima (d-l)-(d-5), kao i u (d-4-a) i (d-5-a): svaki Rla, Rlb, Rlb, Rld, Rld, Rle, R11 je nezavisno bilo koji od supstituenata koji su izabrani iz onih koji su pomenuti kao mogući supstituenti na monocikličkom ili bicikličkom prstenskom sistemu iz R1, kao šta je već specifikovano u zahtevu 1.
7. Jedinjenje u skladu sa zahtevom 6, naznačeno time, da L je -O-, a R4 je neki radikal sa formulom gde R1f je vodonik, C1-6alkil, amino, mono- ili diC1-6alkilamino, pirolidinil, piperidinil, piperazinil, 4-C1-6alkilpiperazinil (a posebno 4-metilpiperazinil) ili morfolinil.
8.Jedinjenje u skladu sa bilo kojim od zahteva od 1-4, naznačeno time, da R3 je (a)R3 je vodonik; ili (b)R3 je C1-6alkil; ili (c)R3 je amino ili mono- ili diC1-6alkilamino.
9.Jedinjenje u skladu sa bilo kojim od zahteva od 1-6, naznačeno time, da nje 4 ili 5.
10.Jedinjenje u skladu sa bilo kojim od zahteva od 1-6, naznačeno time, da R2 je vodonik.
11. Jedinjenje u skladu sa bilo kojim od zahteva od 1-10, naznačeno time, da je različito od N-oksida ili soli.
12. Kombinacija, naznačena time, da obuhvata (a)neko jedinjenje kao šta je definisano u bilo koje od zahteva od 1 do 11 ili neku njegovu farmaceutski prihvatljivu so; i (b)ritonavir ili neku njegovu farmaceutski prihvatljivu so.
13. Farmaceutska kompozicija, naznačena time, da obuhvata neki kerijer i kao aktivni sastojak neku anti-viralno efektivnu količinu nekog jedinjenja kao šta se zahteva u bilo kojem od zahteva od 1-11 ili u kombinaciji u skladu sa zahtevom 12.
14. Jedinjenje u skladu sa bilo kojem od zahteva od 1-11 ili kombinacija u skladu sa zahtevom 12, naznačeni time, da se koriste kao lek.
15. Jedinjenje u skladu sa bilo kojim od zahteva od 1-11 ili kombinacija u skladu sa zahtevom 12, naznačeni time, da se koriste kao inhibitori HCV replikacije.
16. Proces za pripremu jedinjenja kao šta se zahteva u bilo kojem od zahteva od 1-11, naznačen time, da pomenuti proces obuhvata: (a) preparaciju jedinjenja sa formulom (I) gde veza između C7 i C8 je dvostruka veza, šta predstavlja jedinjenje sa formulom (I-i), uz pomoć formiranja dvostruke veze među C7 i C8, a posebno preko neke olefin metatezne reakcije, uz prateću ciklizaciju na makrociklu kao šta je navedeno u sledećoj reakcionoj šemi: gde u gornjim i u idućim strukturnim formulama, grupa je predstavljena sa -R1; (b) konvertovanje jedinjenje sa formulom (I-i) ujedinjenje sa formulom (I) gde spoj među C7 i C8 u makrociklu je jednostruka veza, tj. ujedinjenje sa formulom (I- j): uz pomoć redukovanja C7-C8 dvostruke veze u pomenutom jedinjenju sa formulom (I-j); (c)formiranje amidne veze među intermedijara (2a) i sulfonilamida (2b), kao šta je navedeno u sledećoj šemi gde G predstavlja neku grupu: (d)preparaciju jedinjenja sa formulom (I) gde R3 je vodonik, a pomenuto jedinjenje je predstavljeno sa (I-L), iz odgovarajućeg azot-zaštićenog intermedijara (3a), gde PG predstavlja neku azot-zaštitnu grupu: (e)reagovanje intermedijara (4a) sa intermedijarom (4b), (4c), (4d), (4e) ili (4f) kao šta je navedeno u sledećoj reakcionoj šemi: gde Y u (4a) predstavlja hidroksi ili neku izlaznu grupu; a koja reakcija posebno predstavlja neku O-arilacionu reakciju gde Y je neka izlazna grupa ili neku Mitsunobu-ovu reakciju gde Y je hidroksi; i gde (4a) i (4c) ili (4d) su reagovani u prisutnosti nekog agensa koji uvodi karbonil sa ciljem da se formira L koji je neka uretanska grupa (L je -O-C(=O)- NR5a-); i gde (4a) i (4e) su reagovani u proceduri koja dovodi do nastanka nekog estera; i gde (4a) i (4f) su reagovani u proceduri koja dovodi do nastanka etara; (f)konvertovanje jedinjenja sa formulom (I) jedno u drugo uz pomoć reakcije transformacije funkcionalnih grupa; ili (g)preparaciju neke solne forme uz pomoć reagovanja slobodne forme nekog jedinjenja sa formulom (I) sa nekom kiselinom ili nekom bazom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107073 | 2005-07-29 | ||
| EP05107416 | 2005-08-11 | ||
| PCT/EP2006/064819 WO2007014925A1 (en) | 2005-07-29 | 2006-07-28 | Macrocylic inhibitors of hepatitis c virus |
| EP06764267A EP1912997B1 (en) | 2005-07-29 | 2006-07-28 | Macrocyclic inhibitors of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01318B true ME01318B (me) | 2013-12-20 |
Family
ID=37032218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-194A ME01318B (me) | 2005-07-29 | 2006-07-28 | Makrociklički inhibitori virusa hepatitisa C |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8227407B2 (me) |
| EP (1) | EP1912997B1 (me) |
| JP (1) | JP5230417B2 (me) |
| CN (1) | CN101282978B (me) |
| AR (1) | AR055361A1 (me) |
| AT (1) | ATE524475T1 (me) |
| BR (1) | BRPI0614637A2 (me) |
| CY (1) | CY1112147T1 (me) |
| DK (1) | DK1912997T3 (me) |
| ES (1) | ES2373685T3 (me) |
| HR (1) | HRP20110885T1 (me) |
| ME (1) | ME01318B (me) |
| MY (1) | MY139923A (me) |
| PL (1) | PL1912997T3 (me) |
| PT (1) | PT1912997E (me) |
| RS (1) | RS52058B (me) |
| SI (1) | SI1912997T1 (me) |
| TW (1) | TW200745061A (me) |
| WO (1) | WO2007014925A1 (me) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| RU2436787C2 (ru) | 2005-07-29 | 2011-12-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| EP1919904B1 (en) * | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| BRPI0614637A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos do vìrus da hepatite c |
| WO2007014922A1 (en) * | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008059046A1 (en) * | 2006-11-17 | 2008-05-22 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| RU2481340C2 (ru) * | 2007-02-08 | 2013-05-10 | Тиботек Фармасьютикалз Лтд. | Пиримидин-замещенные макроциклические ингибиторы hcv |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008137779A2 (en) * | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2686546A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| JP2011503201A (ja) | 2007-11-14 | 2011-01-27 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤 |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| RU2490272C2 (ru) * | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| CA2719008A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2009330333A1 (en) * | 2008-12-22 | 2011-07-07 | Gilead Sciences, Inc. | Antiviral compounds |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| MX2011006890A (es) | 2008-12-23 | 2011-07-20 | Pharmasset Inc | Analogos de nucleosidos. |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| CN105001302A (zh) * | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| AP2012006535A0 (en) | 2010-03-31 | 2012-10-31 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorous containing actives |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
| ES3056006T3 (en) * | 2010-12-17 | 2026-02-17 | Univ Southern California | Methods and devices for using isoperillyl alcohol |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| HRP20180237T4 (hr) | 2011-09-16 | 2020-12-11 | Gilead Pharmasset Llc | Metode za liječenje hcv-a |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| EP3484528B1 (en) | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| PL192628B1 (pl) | 1996-04-23 | 2006-11-30 | Vertex Pharma | Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji |
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| WO2001016300A2 (en) | 1999-08-31 | 2001-03-08 | Basf Aktiengesellschaft | Method of identifying inhibitors of cdc25 |
| FR2803203B1 (fr) | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
| KR100926244B1 (ko) | 2001-07-11 | 2009-11-12 | 버텍스 파마슈티칼스 인코포레이티드 | 브릿지된 바이사이클릭 세린 프로테아제 억제제 |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| EP1497282A2 (en) | 2002-04-11 | 2005-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| EP1673385B1 (en) * | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2336009T3 (es) * | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| WO2007014922A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| AR055105A1 (es) * | 2005-07-29 | 2007-08-08 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de la hepatitis c |
| EP1910347A2 (en) * | 2005-07-29 | 2008-04-16 | Medivir Ab | Macrocylic inhibitors of hepatitis c virus |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| EP1919904B1 (en) * | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| ATE496042T1 (de) | 2005-07-29 | 2011-02-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| BRPI0614637A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos do vìrus da hepatite c |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| RU2436787C2 (ru) | 2005-07-29 | 2011-12-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
-
2006
- 2006-07-28 BR BRPI0614637-6A patent/BRPI0614637A2/pt not_active Application Discontinuation
- 2006-07-28 ME MEP-2011-194A patent/ME01318B/me unknown
- 2006-07-28 SI SI200631188T patent/SI1912997T1/sl unknown
- 2006-07-28 DK DK06764267.8T patent/DK1912997T3/da active
- 2006-07-28 EP EP06764267A patent/EP1912997B1/en not_active Expired - Lifetime
- 2006-07-28 CN CN2006800350583A patent/CN101282978B/zh not_active Expired - Fee Related
- 2006-07-28 MY MYPI20063665A patent/MY139923A/en unknown
- 2006-07-28 PT PT06764267T patent/PT1912997E/pt unknown
- 2006-07-28 WO PCT/EP2006/064819 patent/WO2007014925A1/en not_active Ceased
- 2006-07-28 RS RS20110542A patent/RS52058B/sr unknown
- 2006-07-28 PL PL06764267T patent/PL1912997T3/pl unknown
- 2006-07-28 AT AT06764267T patent/ATE524475T1/de active
- 2006-07-28 HR HR20110885T patent/HRP20110885T1/hr unknown
- 2006-07-28 TW TW095127591A patent/TW200745061A/zh unknown
- 2006-07-28 AR ARP060103311A patent/AR055361A1/es unknown
- 2006-07-28 JP JP2008523381A patent/JP5230417B2/ja not_active Expired - Fee Related
- 2006-07-28 ES ES06764267T patent/ES2373685T3/es not_active Expired - Lifetime
-
2008
- 2008-01-16 US US11/995,835 patent/US8227407B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 CY CY20111101239T patent/CY1112147T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200745061A (en) | 2007-12-16 |
| RS52058B (sr) | 2012-04-30 |
| US20090062311A1 (en) | 2009-03-05 |
| JP2009502888A (ja) | 2009-01-29 |
| RU2008107768A (ru) | 2009-09-10 |
| DK1912997T3 (da) | 2012-01-02 |
| ES2373685T3 (es) | 2012-02-07 |
| CY1112147T1 (el) | 2015-11-04 |
| CN101282978B (zh) | 2012-07-11 |
| JP5230417B2 (ja) | 2013-07-10 |
| BRPI0614637A2 (pt) | 2011-04-12 |
| HRP20110885T1 (hr) | 2011-12-31 |
| CN101282978A (zh) | 2008-10-08 |
| US8227407B2 (en) | 2012-07-24 |
| PT1912997E (pt) | 2011-12-19 |
| EP1912997B1 (en) | 2011-09-14 |
| EP1912997A1 (en) | 2008-04-23 |
| MY139923A (en) | 2009-11-30 |
| ATE524475T1 (de) | 2011-09-15 |
| SI1912997T1 (sl) | 2012-02-29 |
| PL1912997T3 (pl) | 2012-02-29 |
| AR055361A1 (es) | 2007-08-22 |
| WO2007014925A1 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110885T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| AU651986B2 (en) | Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same | |
| RU2008107738A (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AU572405B2 (en) | Heterocyclic-substituted indole | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| PE20011096A1 (es) | COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE QUINASAS | |
| AR072162A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| ATE126216T1 (de) | Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung. | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| ATE174596T1 (de) | Imidazo (1,2-a)pyridine als bradykinin- antagonisten | |
| KR910009682A (ko) | 벤족사진 유도체 및 이를 함유하는 약제학적 조성물 | |
| DE3065304D1 (en) | Morpholine derivatives, pharmaceutical compositions containing them and processes for their preparation | |
| WO2008010048A3 (en) | Novel 2-substituted methyl penam derivatives | |
| NZ334971A (en) | 2-cyanoiminoimidazole derivatives for use as phosphodiesterase (PDE) IV inhibitors | |
| NZ333591A (en) | Thiazole compounds, process of manufacture and their use for treating prophylaxis and other diseases | |
| AR044940A1 (es) | Compuestos heterociclicos y su uso como moduladores de gamma opioides | |
| PT76574B (fr) | Procede de preparation de derives d'imidazo <1,2-a> pyridine et de compositions pharmaceutiques les contenant | |
| NZ513594A (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors | |
| PT76328B (en) | Process for the preparation of pyridinocarboxylic acids esters having an anti-ischemic and anti-hypoxygenic effect and application thereof for the preparation of pharmaceutical compositions having an anti-ischemic and anti-hypoxygenic effect | |
| KR950701921A (ko) | 피리딘 화합물 및 이의 제약학적 용도(pyridine compound and medicinal use thereof) | |
| KR970705555A (ko) | 브라디키닌 길항근으로서 디하이드로피리딘 유도체(dihydropyridine derivatives as bradykinin antagonists) | |
| AU639154B2 (en) | New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them | |
| EP0094727A3 (en) | Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use | |
| MY142238A (en) | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors | |
| WO2009112703A8 (fr) | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent |